Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
Sunshine Biopharmas CFO, Camille Sebaaly, stated, We have received feedback that Twitter is a preferred medium to engage with shareholders.
- Sunshine Biopharmas CFO, Camille Sebaaly, stated, We have received feedback that Twitter is a preferred medium to engage with shareholders.
- We understand that shareholder engagement is paramount in the modern age of transparency and speed of information dissemination.
- Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4.
- In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.